Merck (MRK) announced that Health Canada has granted approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy for the treatment of FIGO 2014 Stage III-IVA cervical cancer. The approval is based on data from the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, which demonstrated statistically significant improvements in progression-free survival and overall survival in patients randomized to KEYTRUDA in combination with CRT compared with patients randomized to placebo plus CRT.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Veeva announces Merck committed to Veeva Vault CRM
- Merck & Co. Hold Rating: Balancing Promising HIV Pipeline with Competitive Challenges and Market Uncertainty
- Senate Claws Back $9 Billion in Aid and Media Spending. Which Stocks Are in the Firing Line?
- Trump says drug tariffs probable by August 1, semis coming soon, Bloomberg says
- Adagene announces regulatory update on development plan for muzastotug